World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
112
Citations
111865
World Ranking
788
National Ranking
479

Immunology

D-Index
113
Citations
118101
World Ranking
421
National Ranking
257

Medicine

D-Index
114
Citations
118249
World Ranking
4611
National Ranking
2504

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award
  • 2017 - Member of the National Academy of Medicine (NAM)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Suzanne L. Topalian is affiliated with Johns Hopkins University in the United States and has contributed extensively to the field of medicine, with a focus on oncology. Their research spans multiple subfields, including oncology, immunology, pulmonary and respiratory medicine, electrical and electronic engineering, and aerospace engineering.

The primary areas of study and research topics include:

  • Cancer Immunotherapy and Biomarkers
  • Polyomavirus and related diseases
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Antenna Design and Analysis
  • Cutaneous Melanoma Detection and Management
  • Bacteriophages and microbial interactions

Suzanne L. Topalian has published numerous scientific papers, with recurring appearances in well-known venues such as the Journal of Clinical Oncology, Regular and Young Investigator Award Abstracts, Journal for ImmunoTherapy of Cancer, Cancer Research, and Cancer Cell. The venues with the highest frequency of publications include the Journal of Clinical Oncology with 11 publications and the Journal for ImmunoTherapy of Cancer with 7 publications.

Some notable recent papers authored by Suzanne L. Topalian are:

  • Neoadjuvant checkpoint blockade for cancer immunotherapy, 2020, Science
  • Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial, 2020, Journal of Clinical Oncology
  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab, 2023, Journal of Clinical Oncology

Frequent coauthors collaborating with Suzanne L. Topalian include Janis M. Taube, Drew M. Pardoll, William H. Sharfman, Paul Nghiem, and Evan J. Lipson, reflecting interdisciplinary teamwork and a sustained partnership in the research community.

Throughout their career, Suzanne L. Topalian has been recognized by several professional organizations. Notably, they were named a Member of the National Academy of Medicine in 2017 and hold membership in the Association of American Physicians.

Best Publications

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

    Julie R. Brahmer;Scott S. Tykodi;Scott S. Tykodi;Laura Q.M. Chow;Wen Jen Hwu

  • Immune checkpoint blockade: a common denominator approach to cancer therapy

    Suzanne L. Topalian;Charles G. Drake;Drew M. Pardoll

  • Cancer regression in patients after transfer of genetically engineered lymphocytes

    Richard A. Morgan;Mark E. Dudley;John R. Wunderlich;Marybeth S. Hughes

  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

    Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  • Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

    Julie R. Brahmer;Charles G. Drake;Ira Wollner;John D. Powderly

  • A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

    James C. Yang;Leah Haworth;Richard M. Sherry;Patrick Hwu

  • Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

    S A Rosenberg;B S Packard;P M Aebersold;D Solomon

  • Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

    Suzanne L. Topalian;Janis M. Taube;Robert A. Anders;Drew M. Pardoll

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

    Janis M Taube;Alison P. Klein;Julie R Brahmer;Haiying Xu

  • Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

    Janis M. Taube;Robert A. Anders;Geoffrey D. Young;Haiying Xu

  • Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

    Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  • Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

    Patrick M. Forde;Jamie E. Chaft;Kellie N. Smith;Valsamo Anagnostou

  • Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

    Mark E. Dudley;John R. Wunderlich;James C. Yang;Richard M. Sherry

  • Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

    Giao Q. Phan;James C. Yang;Richard M. Sherry;Patrick Hwu

  • Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.

    James C. Yang;Alfred E. Chang;Alan R. Baker;William F. Sindelar

  • Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1

    Eric V. Dang;Joseph Barbi;Huang Yu Yang;Huang Yu Yang;Dilini Jinasena

  • Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction

    Steven A. Rosenberg;Paul Aebersold;Kenneth Cornetta;Attan Kasid

  • Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

    Suzanne L Topalian;Charles G Drake;Drew M Pardoll

Frequent Co-Authors

Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Janis M. Taube
Janis M. Taube Johns Hopkins University
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Douglas J. Schwartzentruber
Douglas J. Schwartzentruber National Institutes of Health
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University
Robert A. Anders
Robert A. Anders Johns Hopkins University School of Medicine
Drew M. Pardoll
Drew M. Pardoll Johns Hopkins University School of Medicine
Mario Sznol
Mario Sznol Yale University
Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
Charles G. Drake
Charles G. Drake Columbia University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, exploring related healthcare degrees can open doors to diverse, rewarding careers. Many immunology graduates find transitioning into nursing or advanced practice roles attractive, offering hands-on patient care and leadership opportunities.

Several programs can accelerate this career shift. For instance, 12-month accelerated nursing programs online for non nurses allow students from non-nursing backgrounds to enter the nursing field swiftly, gaining essential clinical skills in a condensed timeframe.

Once in nursing, professionals might pursue specialized pathways. accelerated nurse practitioner programs offer intensive curricula that prepare graduates for advanced practice roles, including acute care settings.

Specifically, those interested in acute patient management can explore acute care nurse practitioner programs, designed for family nurse practitioners aiming to expand their expertise in high-acuity environments.

Considering specialization is also vital for career growth and salary potential. Information on the highest paid dnp specialties can guide professionals seeking to maximize their earning opportunities while making impactful contributions in healthcare.

Best Scientists Citing Suzanne L. Topalian

Trending Scientists

Recently Published Articles